ANDA 216780, held by Rubicon Research. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 216780 (Lidocaine Hydrochloride), held by Rubicon Research, was first approved by FDA on Mar 28, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Oral Topical Solution 2% (Viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · solution;oral | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters